Revolution Medicines, Inc. (RVMD)
203.77
+0.42
(+0.21%)
USD |
NASDAQ |
Sep 11, 16:00
203.85
+0.08
(+0.04%)
After-Hours: 20:00
Revolution Medicines Shareholders Equity (Quarterly) : 2.606B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.606B |
| March 31, 2026 | 1.500B |
| December 31, 2025 | 1.631B |
| September 30, 2025 | 1.597B |
| June 30, 2025 | 1.865B |
| March 31, 2025 | 2.078B |
| December 31, 2024 | 2.265B |
| September 30, 2024 | 1.566B |
| June 30, 2024 | 1.619B |
| March 31, 2024 | 1.725B |
| December 31, 2023 | 1.826B |
| September 30, 2023 | 837.46M |
| June 30, 2023 | 930.84M |
| March 31, 2023 | 952.22M |
| December 31, 2022 | 685.19M |
| September 30, 2022 | 681.42M |
| Date | Value |
|---|---|
| June 30, 2022 | 498.84M |
| March 31, 2022 | 550.99M |
| December 31, 2021 | 602.57M |
| September 30, 2021 | 638.20M |
| June 30, 2021 | 685.01M |
| March 31, 2021 | 722.58M |
| December 31, 2020 | 474.68M |
| September 30, 2020 | 505.07M |
| June 30, 2020 | 360.50M |
| March 31, 2020 | 385.32M |
| December 31, 2019 | 152.54M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 96.66M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Erasca, Inc. | 361.87M |
| Moderna, Inc. | 6.761B |
| Tango Therapeutics, Inc. | 1.025B |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Intellia Therapeutics, Inc. | 727.71M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 4.323B |
| Total Liabilities (Quarterly) | 1.717B |
| Debt to Equity Ratio | 0.4568 |
| Current Ratio | 11.38 |
| Net Debt Paydown Yield | -0.53% |